Celularity Inc (CELU)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.73-10.32%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · CELU
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -86.5% |
| Our one-year growth estimate | diamond | -24.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 62.5 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
CELU — officer change
Dated 2026-09-29
Director — Naveen Jain: The filing discloses the appointment of a new director (Naveen Jain) and the concurrent resignation of another director (Diane Parks) as part of a financing agreement, which is a board composition change rather than the departure of a senior executive officer.
Why it matters: Management named both products as commercial priorities. Sales and repeat use would show whether the plan is gaining traction.
Supportive ifThe November 13 earnings update reports higher cenplacel-L sales or use by more physicians. It also reports higher Lifebank sales than in the prior period.
Worry ifThe update reports lower sales or use for both products, or gives no signs of progress in either business.
Why it matters: FDA rules may decide whether these APIs can reach the intended compounding pharmacies. The deal excludes weight-loss peptides.
Watch forFDA lists a Peptual peptide substance and form for use in compounding under federal law.
Also watch forFDA does not list the relevant substance or form, or limits its use so the planned pharmacy supply cannot proceed.
Why it matters: The deal adds a new manufacturing business. It cannot bring in revenue until the process meets quality rules and products can ship.
Supportive ifCelularity says its process and quality checks are complete. It names a Peptual API lot released for commercial supply.
Worry ifCelularity reports failed or delayed process checks. Or it says it cannot meet quality rules or supply terms.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$346 on $10,000 · ±3.5% | How much price usually moves either way. |
| Bad day | $1,005 loss on $10,000 · 10.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,040 loss on $10,000 · 70.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.